Nuclear medicine physician Lisa Bodei, MD, Ph.D., who is Director of Targeted Radionuclide Therapy at MSK, is working with nuclear medicine physician Mark Dunphy, DO, and Dr. Rudin to develop and ...

Dr. Mark Dunphy Neuroendocrine prostate cancer is rare but very deadly with no effective standard therapy. It can arise as a new cancer (called “de novo”).

On the C-SPAN Networks: Mark Dunphy is a Professor for English in the Lindsey Wilson College with one video in the C-SPAN Video Library; the first appearance was a 2002 Forum. Scholars examined ...